复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准

证券之星06-15 19:19

复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2643270025?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-15 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643270025","market":"hk","top_or_hot":-1,"title":"复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600196\">复星医药</a>(600196.SH)公告称，公司控股子公司上海<a href=\"https://laohu8.com/S/02196\">复星医药</a>产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/58808020260615.png\"/><img src=\"https://static.stockstar.com/etf/15978120260615.png\"/><img src=\"https://static.stockstar.com/etf/51201020260615.png\"/><img src=\"https://static.stockstar.com/etf/51608020260615.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-15 19:19 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026061500028452.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。以上内容为证券之星据公开信息整理，...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026061500028452.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://stock.stockstar.com/RB2026061500028452.shtml","article_id":"2643270025","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643270025","pubTimestamp":1781522392,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0188":"融资融券","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","02196":"复星医药","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"Fosun Pharma's latest announcement: the new indication of its holding subsidiary drug luvolatinib tablets was approved by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643270025","isCrawlerRequest":true}